Actively hiring
Cardiovascular Devices
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$8.5M
3 rounds on record
Latest round
$7.7M
Venture round · May 2023 · 3 yr ago
Backers
1
Good Growth Capital
The money's age
Long since its last round
41 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Mar 9
Certified Pleural Dynamics Receives FDA 510(k) Clearance for its Novel ACES System · pleuraldynamics.com
Oct 27, 2025
Took on debt financing $618k · SEC Form D
Oct 19, 2023
Certified Pleural Dynamics Receives FDA 510(k) Clearance for its Novel ACES Automatic Continuous Effusion Shunt System · streetinsider.com
May 25, 2023
Board appointment Amy Salzhauer, Director · SEC Form D
May 10, 2023
Raised a round Venture round $7.7M · SEC Form D
Apr 8, 2020
Raised a round Venture round $835k · SEC Form D
2020
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Oct 2025 | $618k | — | SEC Form D |
| Venture round | May 2023 | $7.7M | — | SEC Form D |
| Venture round | Apr 2020 | $835k | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Pleural Dynamics, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Martin MayseExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers

Puracath reduces catheter infection risks with UV tech. Streamlined disinfection process. Contact us in San Francisco, CA for details.

VitalPath is a leading medical device contract manufacturer 100% focused on complex catheter design, rapid prototyping, and full-scale ISO…

Xeltis is an international medical technology company developing vascular and valve implants that transform into living blood vessels…

Capcyte provides bioactive surface treatments for better cardiovascular implants and cell culture devices.

Capstan Medical develops robotically delivered heart valve implants for minimally invasive structural heart repair. Its system combines a…

Implant-free cryotherapy. Solutions to stabilize vulnerable plaques and reduce heart attack risk.
News
Study Demonstrates Significant Reduction in Pleural Effusion Volume Using Pleural Dynamics' ACES Fully-Implantable System
October 28, 2025 - Pleural Dynamics, Inc. today announced positive results from a prospective, multicenter study evaluating its Automatic Continuous Effusion Shunt (ACES) device for the management of symptomatic recurrent pleural effusions. The study, pre
Read more
Report
CMS Grants HCPCS Code and NTAP Classification for Pleural Dynamics' Novel ACES Automatic Continuous Effusion Shunt
October 14, 2025 -The Centers for Medicare and Medicaid Services (CMS) has issued a new Healthcare Common Procedure Coding System (HCPCS) code and New Technology Ambulatory Payment Classification (New Technology APC) assignment for the ACES (Automatic Con
Read more
Report
The ACES Study for Aseptic Pleural Effusions
Aug 19, 2025 Pleural Dynamics Announces Completion of Enrollment of "The ACES Study for Aseptic Pleural Effusions," a Post Market Study Evaluating the Novel ACES Automatic Continuous Effusion Shunt System Pleural Dynamics' innovative, fully implantable, p
Read more
Report
Memorial Healthcare System Participates in GroundbreakingClinical Trial for Innovative Pleural Effusion Treatment
March 27, 2025 - Memorial Healthcare System is one of only four healthcare centers in the nation to have participated in a clinical trial for the Pleural Dynamics ACES System, a game-changing device that uses a patient's normal breathing to provide contin
Read more
Report
Pleural Dynamics Receives FDA 510(k) Clearance for its Novel ACES System
Pleural Dynamics is the first and only company with a fully implantable automatic effusion shunt with no external catheters or expensive drainage canisters, providing an innovative new option for pleural effusion care. Wayzata, MN - October 17, 2023 - Ple
Read more
Report
Pleural Dynamics Treats First Patient in "The ACES Study for Aseptic Pleural Effusions", a Post Market Clinical Study for its Novel ACES Automatic Continuous Effusion Shunt System
Pleural Dynamics brings to patients the first and only fully implantable automatic effusion shunt with no external catheters or expensive drainage canisters to patients, providing an innovative new option for pleural effusion care. Wayzata, MN - June 26,
Read more
Report
Study Demonstrates Significant Reduction in Pleural Effusion Volume Using Pleural Dynamics' ACESFully-Implantable System
PLYMOUTH, Minn., October 28, 2025--Pleural Dynamics, Inc. today announced positive results from a prospective, multicenter study evaluating its Automatic Continuous Effusion Shunt (ACES) device for the management of symptomatic recurrent pleural effusions
Read more
Report
CMS Grants HCPCS Code and NTAP Classification for Pleural Dynamics' Novel ACES Automatic Continuous Effusion Shunt
Read more
Report
Pleural Dynamics Announces Completion of Enrollment of "The ACES Study for Aseptic Pleural Effusions," a Post Market Study Evaluating the Novel ACES Automatic Continuous Effusion Shunt System
MINNEAPOLIS, August 19, 2025--Pleural Dynamics has enrolled the final patient in "The ACES Study for Aseptic Pleural Effusions" post-market clinical study.
Read more
Report
Report
Show more news
People

Martin Mayse
Executive Officer, Director

Gintaras Vaisnys
Director

Richard Stark
Director

Robert Crutchfield
Director

Mark Deem
Director

Amy Salzhauer
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Wayzata
United States
HQ

Good Growth Capital 




